Skip to main content
. 2020 Dec 22;11(51):4693–4698. doi: 10.18632/oncotarget.27845

Figure 2. NSCs are permissive to vMyx-GFP-TdTr infection.

Figure 2

(A) NSCs were treated with vMyx-GFP-TdTr at an MOI of 10, and infection increased significantly over time post-infection. (B) Similarly, the replication of vMyx-GFP-TdTr increased significantly over time after infection. (C) NSCs were infected with vMyx-GFP-TdTr at various MOIs, and 72 h later showed significantly lower viability relative to non-infected control cells. Data are shown as mean ± SEM for at least two repeated experiments. **** P < 0.0001, as determined by one-way ANOVA comparing infected vs. non-infected cells. ns, no significant difference.